First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Rotow, J. K. [1 ]
Waqar, S. N. [2 ]
Papadopoulos, K. P. [3 ]
Hung, J-Y. [4 ,5 ]
Spira, A. I. [6 ]
Gan, H. [7 ]
Yoshida, T. [8 ]
Kuo, C-H. S. [9 ]
Doger de Speville, B. [10 ]
Felip, E. [11 ]
Yoh, K. [12 ]
Morrison-Thiele, G. [13 ]
Robinson, R. [14 ]
Rudraganguly, N. [14 ]
Saab, R. [15 ]
Cho, B. C. [16 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Washington Univ, Med, Sch Med St Louis, Siteman Canc Ctr, St Louis, MO USA
[3] South Texas Accelerated Res Therapeut START, Dept Clin Res, San Antonio, TX USA
[4] Kaohsiung Med Univ, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan
[5] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Coll Med, Fac Med, Kaohsiung, Taiwan
[6] Virginia Canc Specialists, Dept Med Oncol, US Oncol Res, Fairfax, VA USA
[7] Austin Hlth Austin Hosp, Dept Med Oncol, Heidelberg, Vic, Australia
[8] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[9] Chang Gung Univ, Chang Gung Mem Hosp, Div Thorac Oncol & Intervent Bronchoscopy, Dept Resp Med, Taipei, Taiwan
[10] START Madrid Hosp Univ, Fdn Jimenez Diaz, Madrid, Spain
[11] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[12] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[13] AbbVie Inc, Oncol Early Discovery, Headquarters, N Chicago, IL USA
[14] AbbVie Inc, San Francisco, CA USA
[15] AbbVie Inc, Clin Res, San Francisco, CA USA
[16] Yonsei Univ, Med Oncol Dept 501, ABMRC, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318MO
引用
收藏
页数：1
相关论文
共 48 条
  • [41] A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC)
    Burris, Howard A.
    Gordon, Michael S.
    Gerber, David E.
    Spigel, David R.
    Mendelson, David S.
    Schiller, Joan H.
    Wang, Yulei
    Choi, Younleong
    Kahn, Robert S.
    Wood, Katie
    Maslyar, Daniel J.
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
    Tan, Daniel Shao-Weng
    Seto, Takashi
    Leighl, Natasha B.
    Riely, Gregory J.
    Sequist, Lecia V.
    Felip, Enriqueta
    Wolf, Juergen
    Yang, James Chih-Hsin
    Matushansky, Igor
    Yu, Xiaolu
    Schmitz, Shu-Fang Hsu
    Cui, Xiaoming
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] EGFR-targeting Chimeric Monoclonal IgG-1 Antibody Cetuximab in a Phase II/III Study Added Either to Gemcitabine Followed by Docetaxel or Carboplatin Plus Gemcitabine for Chemonaive Patients With Advanced Non-small Cell Lung Cancer (NSCLC) - Results of the Phase II Study Part
    Kortsik, C.
    Schmid-Bindert, G.
    Pilz, L. R.
    Cicenas, S.
    Eschbach, C.
    Kollmeier, J.
    Schumann, C.
    Serke, M.
    Steins, M.
    Manegold, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S621 - S621
  • [44] ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PHASE II/III STUDY IN CHEMONAIVE PATIENTS: EGFR-TARGETING CHIMERIC MONOCLONAL IGG-1 ANTIBODY CETUXIMAB ADDED EITHER TO GEMCITABINE FOLLOWED BY DOCETAXEL OR CARBOPLATIN PLUS GEMCITABINE. RESULTS OF THE PHASE II STUDY PART
    Schmid-Bindert, Gerald
    Cicenas, Saulius
    Eschbach, Corinna
    Kollmeier, J.
    Kortsik, Cornelius
    Schumann, Christian
    Serke, Monika
    Steins, Martin
    Manegold, Christian
    Pilz, Lothar R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1229 - S1230
  • [45] Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: Interim analysis of an rw pt registry in Germany
    Griesinger, F.
    Popat, S.
    Okhuoya, P.
    Servidio, L.
    Fonseca, M. J.
    Tolani, E.
    Lu, S.
    Zacharias, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1587
  • [46] A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).
    Schaefer, Eric S.
    Camidge, D. Ross
    Yoh, Kiyotaka
    Zer, Alona
    Guerrero, Tatiana Hernandez
    Bar, Jair
    Okuma, Yusuke
    Peguero, Julio Antonio
    De Miguel, Maria
    Moskovitz, Mor Tal
    Morgensztern, Daniel
    Jeffries, Shawn
    Wang, Lan
    Lally, Satwant
    Conn, Christopher
    Xin, Xiaohua
    Jeng, Edwin E.
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
    Richardson, Debra L.
    Barve, Minal A.
    Strauss, James Fredric
    Ulahannan, Susanna Varkey
    Moore, Kathleen N.
    Hamilton, Erika Paige
    Johnson, Melissa Lynne
    Papadopoulos, Kyriakos P.
    Zarwan, Corrine
    Anderson, Charles K.
    Buscema, Joseph
    Doroshow, Deborah Blythe
    Edenfield, William Jeffery
    Matulonis, Ursula A.
    Burns, Timothy F.
    Huebner, Dirk
    Jansen, Valerie Malyvanh
    Mosher, Rebecca
    Jarlenski, Donna
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
    Shimizu, Toshio
    Sands, Jacob
    Yoh, Kiyotaka
    Spira, Alexander
    Garon, Edward B.
    Kitazono, Satoru
    Johnson, Melissa L.
    Meric-Bernstam, Funda
    Tolcher, Anthony W.
    Yamamoto, Noboru
    Greenberg, Jon
    Kawasaki, Yui
    Zebger-Gong, Hong
    Kobayashi, Fumiaki
    Phillips, Penny
    Lisberg, Aaron E.
    Heist, Rebecca S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (29) : 4678 - +
12345